Brokerages Set BioNTech SE (NASDAQ:BNTX) Price Target at $140.76

BioNTech SE (NASDAQ:BNTX) has been given a consensus recommendation of “Moderate Buy” by the seventeen ratings firms that are presently covering the company, Marketbeat reports. Four analysts have rated the stock with a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $140.76.

Several equities analysts have issued reports on BNTX shares. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. TD Cowen decreased their price target on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research note on Tuesday, November 5th. Canaccord Genuity Group boosted their price objective on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research note on Wednesday, November 27th. Deutsche Bank Aktiengesellschaft lifted their price target on BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. Finally, UBS Group increased their price objective on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th.

BioNTech Price Performance

NASDAQ:BNTX opened at $114.13 on Friday. The firm’s fifty day moving average is $113.05 and its two-hundred day moving average is $101.06. The firm has a market cap of $27.13 billion, a price-to-earnings ratio of -54.35 and a beta of 0.22. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech has a one year low of $76.53 and a one year high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s quarterly revenue was up 38.9% on a year-over-year basis. During the same period last year, the business earned $0.73 earnings per share. Research analysts expect that BioNTech will post -3.72 EPS for the current year.

Hedge Funds Weigh In On BioNTech

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Exome Asset Management LLC purchased a new position in BioNTech in the third quarter valued at about $4,104,000. Vestcor Inc acquired a new position in shares of BioNTech in the 3rd quarter valued at approximately $784,000. Y Intercept Hong Kong Ltd purchased a new position in shares of BioNTech during the 3rd quarter valued at approximately $718,000. XTX Topco Ltd acquired a new stake in shares of BioNTech during the third quarter worth approximately $459,000. Finally, State Street Corp increased its stake in shares of BioNTech by 2.0% in the third quarter. State Street Corp now owns 155,867 shares of the company’s stock worth $18,512,000 after buying an additional 3,014 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.